Eric Salgado
Overview
Explore the profile of Eric Salgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salgado E, Cao Y
Antibodies (Basel)
. 2022 Apr;
11(2).
PMID: 35466281
Immune checkpoint blockades prescribed in the neoadjuvant setting are now under active investigation for many types of tumors, and many have shown early success. The primary tumor (PT) and tumor-draining...
2.
Salgado E, Cao Y
Math Biosci Eng
. 2021 Feb;
18(1):112-131.
PMID: 33525083
The signaling axis from the primary tumor to the tumor-draining lymph node (TDLN) has emerged as a crucial mediator for the efficacy of immunotherapies in neoadjuvant settings, challenging the primary...
3.
Gurbani S, Weinberg B, Salgado E, Voloschin A, Velazquez Vega J, Olson J, et al.
Oxf Med Case Reports
. 2020 Apr;
2020(3):omaa006.
PMID: 32257248
Secondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and...
4.
Bai R, Jie X, Sun J, Liang Z, Yoon Y, Feng A, et al.
Eur J Med Chem
. 2019 Apr;
173:32-43.
PMID: 30981691
The CXCR4/CXCL12 axis plays prominent roles in tumor metastasis and inflammation. CXCR4 has been shown to be involved in a variety of inflammation-related diseases. Therefore, CXCR4 is a promising potential...
5.
Gurbani S, Yoon Y, Weinberg B, Salgado E, Press R, Scott Cordova J, et al.
Tomography
. 2019 Mar;
5(1):53-60.
PMID: 30854442
Histone deacetylases regulate a wide variety of cellular functions and have been implicated in redifferentiation of various tumors. Histone deacetylase inhibitors (HDACi) are potential pharmacologic agents to improve outcomes for...
6.
Salgado E, Bian X, Feng A, Shim H, Liang Z
Biochem Biophys Res Commun
. 2018 Jun;
503(2):1087-1091.
PMID: 29936177
Triple negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes with poor prognosis. The purpose of this study is to better understand the molecular basis of TNBC...
7.
Bai R, Sun J, Liang Z, Yoon Y, Salgado E, Feng A, et al.
Eur J Med Chem
. 2018 Mar;
150:195-205.
PMID: 29529500
The CXCR4/CXCL12 chemokine axis can chemotactically accumulate inflammatory cells to local tissues and regulate the release of inflammatory factors. Developing novel CXCR4 modulators may provide a desirable strategy to control...
8.
Bian X, Liang Z, Feng A, Salgado E, Shim H
Biochem Pharmacol
. 2017 Nov;
147:30-37.
PMID: 29155146
Although histone deacetylase (HDAC) inhibitors have been shown to effectively induce the inhibition of proliferation and migration in breast cancer, the anticancer mechanism remains poorly understood. Our studies show that...
9.
Bai R, Liang Z, Yoon Y, Salgado E, Feng A, Gurbani S, et al.
Eur J Med Chem
. 2017 May;
136:360-371.
PMID: 28521261
CXCR4 plays a crucial role in the inflammatory disease process, providing an attractive means for drug targeting. A series of novel amide-sulfamide derivatives were designed, synthesized and comprehensively evaluated. This...